bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-2-190-199bloodjour-547Research ArticleОБЗОРЫREVIEWSПрофилактика ишемического инсульта у больных миелопролиферативными новообразованиямиPrevention of ischemic stroke in patients with myeloproliferative neoplasmshttps://orcid.org/0000-0002-4626-6520КузнецоваП. И.KuznetsovaP. I.

Кузнецова Полина Игоревна,  кандидат медицинских наук, научный сотрудник 1-го неврологического отделения

125367, г. Москва

Polina I. Kuznetsova, Cand. Sci. (Med.), researcher, neurologist, 1st neurological department

125367, Moscow

kuznetsova@neurology.ruhttps://orcid.org/0000-0002-2119-3775МеликянА. Л.MelikyanA. L.

Меликян Анаит Левоновна, доктор медицинских наук, заведующая отделением стандартизации методов лечения

125167, г. Москва

Anait L. Melikyan, Dr. Sci. (Med.), head of the department of standardization and treatment methods

125167, Moscow

anoblood@mail.ruhttps://orcid.org/0000-0001-9045-8653СуборцеваИ. Н.SubortsevaI. N.

Суборцева Ирина Николаевна, кандидат медицинских наук, гематолог отделения стандартизации методов лечения гематологических заболеваний, старший научный сотрудник отдела диагностики и лечения гематологических заболеваний

125167, г. Москва

Irina N. Subortseva,  Cand. Sci. (Med.), researcher, hematologist, department of standardization and treatment methods

125167, Moscow

soubortseva@yandex.ruhttps://orcid.org/0000-0003-0522-767XРаскуражевА. А.RaskurazhevA. A.

Раскуражев Антон Алексеевич,  кандидат медицинских наук, научный сотрудник 1-го неврологического отделения

125367, г. Москва

Anton A. Raskurazhev, Cand. Sci. (Med.), researcher, neurologist, 1st neurological department

125367, Moscow

rasckey@live.comhttps://orcid.org/0000-0002-5883-8119ТанашянМ. М.TanashyanM. M.

Танашян Маринэ Мовсесовна, доктор медицинских наук, профессор, член-корреспондент РАН, заместитель директора по научной работе, заведующая 1-м неврологическим отделением

125367, г. Москва

Marine M. Tanashyan,  Dr. Sci. (Med.), Professor, Corr. Member of the RAS, Deputy director for science, Head of the 1st neurological department

125367, Moscow

mtanashyan@neurology.ruФГБНУ «Научный центр неврологии»РоссияResearch Center of NeurologyRussian FederationФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202418082024692190199Copyright © Кузнецова П.И., Меликян А.Л., Суборцева И.Н., Раскуражев А.А., Танашян М.М., 20242024Кузнецова П.И., Меликян А.Л., Суборцева И.Н., Раскуражев А.А., Танашян М.М.Kuznetsova P.I., Melikyan A.L., Subortseva I.N., Raskurazhev A.A., Tanashyan M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/547Введение

Введение. Миелопролиферативные новообразования (МПН) являются редкой, но значимой причиной инсультов.

Цель

Цель: поиск и описание факторов риска развития инсульта, а также стратегий профилактики по имеющимся литературным данным у больных МПН.

Основные сведения

Основные сведения. В онлайн-базах данных (PubMed, E-Library) был проведен поиск исследований, посвященных церебральным тромботическим осложнениям на фоне МПН. Индукцию специфического циторедуктивного лечения в  сочетании с  низкими дозами ацетилсалициловой кислоты следует рассматривать как неотъемлемый компонент вторичной профилактики некардиоэмболических нарушений мозгового кровообращения.

Introduction

Introduction.  Myeloproliferative neoplasms (MPNs) are a rare but significant cause of strokes.

Aim

Aim. To describe risk factors for stroke development, as well as  prevention strategies based on available literature data on patients with MPN.

Main findings

Main findings.  Online databases (PubMed, E-Library) were searched for studies on cerebral thrombotic complications in the setting of myeloproliferative disorders. Induction of specific cytoreductive treatment with  low doses of acetylsalicylic ac id should be considered as a mandatory component of secondary prevention of noncardioembolic stroke.

миелопролиферативные новообразованиятромбозинсультгиперкоагуляцияпрофилактикаmyeloproliferative neoplasmsthrombosisstrokehypercoagulationpreventionReferencesMarkus H.S. The global burden of stroke. Int J Stroke. 2023; 18(6): 632–3. DOI: 10.1177/17474930231181677.Markus H.S. The global burden of stroke. Int J Stroke. 2023; 18(6): 632–3. DOI: 10.1177/17474930231181677.https://vizhub.healthdata.org/gbd-compare/https://vizhub.healthdata.org/gbd-compare/Barbui T., Finazzi G., Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122(13): 2176–84. DOI: 10.1182/blood-2013-03-460154.Barbui T., Finazzi G., Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122(13): 2176–84. DOI: 10.1182/blood-2013-03-460154.Реброва О.Ю., Федяева В.К. Вопросник для оценки риска систематических ошибок в нерандомизированных сравнительных исследованиях: русскоязычная версия шкалы Ньюкасл-Оттава. Медицинские технологии. Оценка и выбор. 2016; 3(25): 14–19.Rebrova O.Yu., Fedyaeva V.K. Questionnaire for assessing the risk of systematic errors in randomized comparative studies: the Russian-language version of the Newcastle-Ottawa scale. Medicinskie tekhnologii. Ocenka i vybor. 2016; 3(25): 14-9. (In Russian).Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: 71. DOI: 10.1136/bmj.n71.Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: 71. DOI: 10.1136/bmj.n71.Grunwald M.R., Stein B.L., Boccia R.V., et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018; 18(12): 788–95.e2. DOI: 10.1016/j.clml.2018.08.009.Grunwald M.R., Stein B.L., Boccia R.V., et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018; 18(12): 788–95.e2. DOI: 10.1016/j.clml.2018.08.009.Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95: 1599–613. DOI: 10.1002/ajh.26008.Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95: 1599–613. DOI: 10.1002/ajh.26008.Passamonti F., Rumi E., Pietra D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010 Sep; 24(9): 1574–9. DOI: 10.1038/leu.2010.148.Passamonti F., Rumi E., Pietra D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010 Sep; 24(9): 1574–9. DOI: 10.1038/leu.2010.148.Waggoner M. Polycythemia Vera: Thinking Beyond the Hematocrit. J Adv Pract. Oncol. 2023 Jul; 14(5): 405–13. D OI: 10.6004/jadpro.2023.14.5.5.Waggoner M. Polycythemia Vera: Thinking Beyond the Hematocrit. J Adv Pract. Oncol. 2023 Jul; 14(5): 405–13. D OI: 10.6004/jadpro.2023.14.5.5.Burattini M., Falsetti L., Potente E., et al. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review. Rev Neurosci. 2021; 33(3): 303–11. D OI: 10.1515/revneuro-2021-0066.Burattini M., Falsetti L., Potente E., et al. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review. Rev Neurosci. 2021; 33(3): 303–11. D OI: 10.1515/revneuro-2021-0066.Haider M., Gangat N., Lasho T., et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016; 91(4): 390–4. DOI: 10.1002/ajh.24293.Haider M., Gangat N., Lasho T., et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016; 91(4): 390–4. DOI: 10.1002/ajh.24293.Carobbio A., Thiele J., Passamonti F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22): 5857–9. DOI: 10.1182/blood-2011-02-339002.Carobbio A., Thiele J., Passamonti F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22): 5857–9. DOI: 10.1182/blood-2011-02-339002.Latagliata R., Montanaro M., Cedrone M., et al. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thromb Res. 2017; 156: 168–71. DOI: 10.1016/j.thromres.2017.06.023.Latagliata R., Montanaro M., Cedrone M., et al. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thromb Res. 2017; 156: 168–71. DOI: 10.1016/j.thromres.2017.06.023.Das S., Deb A., Pal T. Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. Med Princ Pract. 2021; 30(5): 412–21. DOI: 10.1159/000516471.Das S., Deb A., Pal T. Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. Med Princ Pract. 2021; 30(5): 412–21. DOI: 10.1159/000516471.Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012; 119(119): 3595–603.Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012; 119(119): 3595–603.Dragani A., Pascale S., Recchiuti A., et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010; 115(5): 1054–61.Dragani A., Pascale S., Recchiuti A., et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010; 115(5): 1054–61.Dillinger J.G., Sideris G., Henry P., et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012; 129(129): 91–4.Dillinger J.G., Sideris G., Henry P., et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012; 129(129): 91–4.Mital A., Prejzner W., Bieniaszewska M., et al. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015; 125(12): 914–20.Mital A., Prejzner W., Bieniaszewska M., et al. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015; 125(12): 914–20.Posfai E., Marton I., Szőke A., et al. Stroke in essential thrombocythemia. J Neurol Sci. 2014 Jan 15; 336(1–2): 260–2. DOI: 10.1016/j.jns.2013.10.016.Posfai E., Marton I., Szőke A., et al. Stroke in essential thrombocythemia. J Neurol Sci. 2014 Jan 15; 336(1–2): 260–2. DOI: 10.1016/j.jns.2013.10.016.De Stefano V., Carobbio A., Di Lazzaro V., et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018; 8(3): 25. DOI: 10.1038/s41408-018-0048-9. PMID: 29535299; PMCID: PMC5849668.De Stefano V., Carobbio A., Di Lazzaro V., et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018; 8(3): 25. DOI: 10.1038/s41408-018-0048-9. PMID: 29535299; PMCID: PMC5849668.Finazzi G.; low-dose aspirin in polycythemia (ECLAP). A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol. 2004; 52(5): 285–8. DOI: 10.1016/j.patbio.2004.02.007.Finazzi G.; low-dose aspirin in polycythemia (ECLAP). A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol. 2004; 52(5): 285–8. DOI: 10.1016/j.patbio.2004.02.007.Gangat N., Wolanskyj A.P., Schwager S.M., et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009; 115: 5740–5.Gangat N., Wolanskyj A.P., Schwager S.M., et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009; 115: 5740–5.Stefanou M.I., Richter H., Hartig F., et al. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. Eur J Neurol. 2019; 26(6): 903-e64. DOI: 10.1111/ene.13907.Stefanou M.I., Richter H., Hartig F., et al. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. Eur J Neurol. 2019; 26(6): 903-e64. DOI: 10.1111/ene.13907.Košťal M., Schwarz J., Ovesna P., et al. CZEMP–Czech Group for Ph- Myeloproliferative neoplasms. Phmyeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. J Thromb Thrombolysis. 2021; 51(1): 112–9. DOI: 10.1007/s11239-020-02175-8.Košťal M., Schwarz J., Ovesna P., et al. CZEMP–Czech Group for Ph- Myeloproliferative neoplasms. Phmyeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. J Thromb Thrombolysis. 2021; 51(1): 112–9. DOI: 10.1007/s11239-020-02175-8.Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018; 24(6): 711–20. DOI: 10.1038/s41591-018-0064-0.Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018; 24(6): 711–20. DOI: 10.1038/s41591-018-0064-0.

The authors declare that there are no conflicts of interest present.